Hims & Hers Health has quickly moved back to the center of the market conversation. Shares of HIMS stock (NYSE:HIMS) climbed 6.61% to $30.73 and are now up about 49% over the past week, a move that shows just how aggressively investors are repricing the company ahead of its May 11 earnings report. The rally is not happening in a vacuum. It reflects a broader belief that Hims & Hers is entering a new phase, one that could push the business beyond its original telehealth identity and deeper into branded drug distribution, specialty care, and higher-value treatment categories.
What makes the latest run more interesting is that the stock is still down slightly for the year even after this surge. That detail matters because it suggests the market is not simply extending an already overheated move. Instead, many traders appear to be treating the recent jump as a reset in expectations after a difficult stretch for healthcare growth names. In that sense, the price action looks less like random speculation and more like a high-stakes bet that Hims & Hers can convert recent strategic moves into a stronger long-term earnings profile.
Why investors suddenly turned more bullish
The sharp change in sentiment is being driven by two themes at once. The first is the company’s renewed link to Novo Nordisk and the commercial opportunity tied to GLP-1 weight-loss treatments. The second is rising optimism around peptides and longevity-focused therapies, an area where Hims & Hers has already signaled larger ambitions.
The Novo Nordisk angle is especially important because it changes how investors think about risk. For a while, the market viewed Hims & Hers as a company that could benefit from demand for weight-loss solutions but might remain exposed to uncertainty around compounded products. A stronger path toward distributing FDA-approved therapies gives the company a more durable story. Instead of being seen only as a digital front door for prescriptions, Hims & Hers starts to look like a broader healthcare platform with a better shot at building recurring, higher-quality revenue streams. For more on the company behind Wegovy and its obesity-care strategy, investors can review Novo Nordisk’s corporate updates directly at Novo Nordisk.
That distinction is a big one. Telehealth alone can be a competitive business with modest differentiation. But telehealth combined with branded pharmaceutical access, patient acquisition, and owned infrastructure creates a more compelling investment case. Hims & Hers has already spent heavily to build out more than 1 million square feet of U.S. facility space, including sterile injectable capacity aimed at treatments such as weight loss and hormonal support. If those assets are increasingly tied to branded product distribution, the company could command more strategic value than the market once assigned to it.
There is also a timing advantage to this story. Demand for GLP-1 therapies remains one of the most powerful trends in healthcare and wellness, and investors are constantly looking for companies that can profit from that demand without being pure-play drug developers. Hims & Hers fits that profile. It offers distribution, engagement, subscription relationships, and a consumer-facing brand at a time when healthcare companies are searching for more efficient ways to reach patients.
The peptide and longevity story is gaining weight
While the Novo Nordisk relationship is drawing the headlines, the peptide narrative may be just as important for the stock’s valuation over time. Investors are showing more interest in the possibility that Hims & Hers could open up a new specialty category built around peptides, coenzymes, and GLP/GIP-related therapies. That matters because it expands the conversation from weight loss into the much broader area of longevity and performance-focused healthcare.
The company has already pointed to peptides as a meaningful part of its roadmap and has invested in a California-based manufacturing facility tied to that opportunity. This is one of the reasons the market has become more willing to reward HIMS stock with a premium growth multiple again. The company is no longer being viewed only through the lens of hair loss, dermatology, sexual health, or routine online consultations. Investors are beginning to frame it as a platform that could participate in several fast-growing treatment categories at once.
That platform advantage becomes more meaningful when matched with scale. Hims & Hers serves more than 2.5 million subscribers, and monthly revenue per subscriber has climbed to $83. Those figures suggest the company is not just adding users. It is also improving how much value it captures from each customer relationship. In practical terms, that gives Hims & Hers a better base from which to introduce new treatment categories without starting from scratch on marketing and retention.
The numbers still show a real tension
Even with all of the excitement, the bullish story is not a clean one. Hims & Hers is still in a heavy investment phase, and that is expected to pressure profitability in the near term. For the upcoming quarter, the company expects revenue between $600 million and $625 million. That is still growth, but it is not the only figure the market will care about. Analysts also expect earnings per share of just $0.06, which would represent a steep year-over-year decline of around 70%.
Adjusted EBITDA is also expected to come in well below the prior-year period. That tells investors something important: the company is leaning hard into expansion, but the payoff has not yet shown up in bottom-line performance. Capital expenditures increased 138% year over year in the fourth quarter of 2025, while free cash flow swung to negative $2.57 million from positive $59.5 million a year earlier. Those are not the numbers of a business optimizing for short-term efficiency. They are the numbers of a company spending heavily to support a larger future opportunity.
Part of that spending is tied to manufacturing expansion, and part of it reflects broader growth efforts, including the pending Eucalyptus acquisition, which brings annual recurring revenue above $450 million. Supporters of the stock see those moves as necessary investments that can deepen the company’s moat. Skeptics see a business asking the market to pay today for profits that may still be some distance away.
Why May 11 matters so much
After a 49% jump in just five trading sessions, the May 11 earnings report has become the event that could either validate the rally or interrupt it. Revenue will obviously matter, but management commentary may matter even more. Investors will want specific signals about how the Novo Nordisk relationship could develop, whether demand trends are strong enough to support guidance, and how quickly the company expects margins to stabilize after this period of outsized investment.
The market will also be listening for more clarity around peptides, longevity-focused offerings, and how those products might fit into the business over the next year. Hims & Hers has been building a more ambitious healthcare model, but investors need to hear how management plans to translate that ambition into repeatable, profitable growth. Readers tracking those milestones can also monitor official company materials and earnings updates through the Hims & Hers investor relations page.
For now, the rally in HIMS stock reflects a clear change in mood. Investors are no longer looking at Hims & Hers as a niche telehealth name. They are starting to price it like a company with a chance to become a larger healthcare platform tied to some of the market’s most in-demand categories. That can justify a sharp move higher, but it also means expectations are rising quickly.
The next chapter will depend on execution. If management can show that branded GLP-1 access, peptide expansion, and infrastructure investment are moving toward stronger revenue quality and future margin potential, the recent surge may look like the beginning of a broader re-rating. If not, the stock could face renewed pressure just as quickly as it climbed. That is what makes Hims & Hers one of the more closely watched earnings stories in healthcare right now.
You may also like: HIMS Stock Surges 11% on FDA Peptide Review Optimism
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
